OVER DEZE AFLEVERING

Engels
Verenigde Staten

TRANSCRIPTIE 🔗

OUDE AFLEVERINGEN ZOEKEN

Zoek naar eerdere afleveringen van Breaking Down Biosimilars.

ANDERE AFLEVERINGEN IN DEZE PODCAST

Biosimilars were first introduced into the US market about six years ago, but getting the all-important “patient buy-in” has been a slow process. Many patients are reluctant to switch to a biosimilar if they’re already happy taking a biologic. But another reason is the proliferati…
In this episode, Zoe and Conner check in with several patients who’ve made the switch to a biosimilar to find out how they’re doing. Some patients taking a biosimilar have to travel to an infusion site to receive their medication, while others inject their medication at home. In those c…
When biosimilars were introduced into the US, there was much talk about how much money they could potentially save patients. Getting a biosimilar developed and approved by the US Food & Drug Administration (FDA) is not as rigorous or time-consuming as for a biologic … which was touted as…
The introduction of biosimilars in the US has been hampered by unrealized cost savings, myths and misinformation, and patient hesitancy. Still, many medical professionals see much to be optimistic about in the next few years. New biosimilars will soon be approved for the US market, and expectations…
Disclaimer: De podcast en de illustraties die op deze pagina zijn ingesloten, zijn afkomstig van Global Healthy Living Foundation, eigendom van de eigenaar en niet gelieerd aan of goedgekeurd door Listen Notes, Inc.